Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Breast biopsy & localization · New Jersey | Breast biopsy & localization · New York | |
|---|---|---|
| Surgeons, 2024 | 124 | 288 |
| Medicare fee-for-service cases | 7,063 | 16,847 |
| Growth since 2019 (Medicare FFS) | 0%/yr | +0.4%/yr |
| Forecast cases (Medicare FFS) | 8,480 in 2030 | 18,000 in 2030 |
| Forecast growth | +3.1%/yr to 2030 | +1.1%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 7.1 | 9.9 |
| Medicare Advantage share | 45% | 57% |
| Out of hospital | 39% (−1 pts since 2019) | 43% (+2 pts since 2019) |
| Cases per surgeon | 57 | 58 |
| Top 10 surgeons' share | 22% | 13% |
| Surgeons growing | 32 | 59 |
| New since the base year | 13 | 54 |
| Likely to stop billing it | 15 by 2026 | 29 by 2026 |
| Forecast miss, 1 year (procedure) | 3% | 3% |
| Company payments per surgeon | $3,228 | $2,341 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.